logo-loader
viewEden Research plc

Appointment of Commercial Director

/**/ link{ color: blue }visited{ color: purple } .ad{size:595.3pt 841.9pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.ad{}p.av{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; text-align: center}span.at{font-size:10.0pt}p.aw{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold}p.ax{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; margin-bottom: 12.1pt; margin-left: 0cm; margin-right: 0cm; margin-top: 12.1pt; text-align: center}p.ay{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:12.1pt;margin-right:0cm;margin-bottom: 12.1pt;margin-left:0cm;text-align:justify}p.az{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";text-align:justify}p.ba{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:10.0pt;text-align:justify}span.bb{color:black} table.bc{margin-left:-5.4pt;border-collapse:collapse}td.aj{width:214.6pt;padding:0cm 5.4pt 0cm 5.4pt}p.bd{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";text-align:justify;line-height:150%}span.be{color: black; font-weight: bold}span.bf{color:blue;text-decoration:underline;color:#0070C0}span.bg{font-size:8.0pt;line-height:150%;color:black}span.bh{color:#0070C0}p.bi{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: 107%; text-align: justify}p.bj{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";text-align:justify;line-height:107%} /**/
RNS Number : 8889B
Eden Research plc
12 June 2019
 

 

 

 

12 June 2019

 

Eden Research plc

 

("Eden" or "Company")

 

Appointment of Commercial Director

Eden Research plc (AIM: EDEN), the AIM listed company that develops and supplies breakthrough biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries, is pleased to announce the appointment of Robert ("Rob") Cannings to the new role of Commercial Director, with effect from 12 June 2019. 

For the last ten years, Rob has worked in an entrepreneurial environment at the cutting edge of the agricultural biologicals industry and, prior to that, in key positions with mainstream conventional agrochemicals. With this extensive knowledge, Rob has been effective in developing strategies and market positioning for new conventional and biological products and using this to prioritise the development and commercialisation of new crop protection products globally.

Rob has been Global Product Manager for Chemtura, AgraQuest, and Bayer CropScience where he created global growth and pricing strategies for conventional and biological products and where he was instrumental in the sale of AgraQuest to Bayer for more than $425m.  Most recently, Rob served as Commercial Director at Plant Health Care with responsibility for Europe, the Middle East, Africa and Asia.

Sean Smith, Chief Executive Officer of Eden, said: "We are pleased to welcome Rob to the team at Eden. Rob's detailed understanding of the conventional pesticide and biocontrol products markets globally will be a key asset for the company as it works towards delivering on its ambitious growth plans.  His hands-on experience with the entire process from research and development through to product commercialisation, marketing and sales, will be invaluable to Eden as we accelerate our growth plans by expanding our regulatory and commercial footprint.

Rob's appointment is considered a key hire within the Company's previously announced plans to grow its in-house capabilities through the recruitment of high-calibre staff with relevant experience and track records of demonstrable success."

 

For further information contact:

Eden Research plc

www.edenresearch.com

Sean Smith

Alex Abrey

01285 359 555



Shore Capital (Nomad)

020 7408 4090

Stephane Auton / Patrick Castle




Powerscourt (Financial PR)

020 7250 1446

Nick Dibden

Jana Tsiligiannis

[email protected]

 

 

Notes:

 

Eden Research is a technology development and commercialisation company with intellectual property and expertise in encapsulation, terpenes and environmentally friendly technologies to provide naturally occurring solutions for the global agrochemicals, animal health, and consumer product industries.

 

Eden's encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. The technology uses yeast cells that are a by-product of numerous commercial production processes to deliver a slow release of natural compounds for agricultural and non-agricultural uses. Terpenes are already widely used in the food flavouring, cosmetics and pharmaceutical industries.

 

Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.

 

Eden is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships.

 

The Company has a number of patents and a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of £13m in developing and protecting its intellectual property and seeking regulatory approval for products that rely upon the Company's technologies. Revenues earned by the Company have been modest whilst the Company has concentrated on securing patent protection for its intellectual property, gaining regulatory approvals, identifying suitable industrial partners, and entering into commercial agreements. 

 

In May 2013, the three actives that comprise Eden's first commercial product, Mevalone, were approved as new ingredients for use in plant protection products. This represented a major milestone in the commercialisation of Eden's technology and is a significant accomplishment for any company.  To illustrate this point, one should note that in all of 2013, Eden's approvals represented 3 of only 10 new active ingredients approved by the EC.

 

Mevalone has been authorised for sale in Kenya, Malta, Greece, Bulgaria, Spain, Italy, France, Cyprus, Albania, Portugal and Macedonia.

 

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN.

 

For more information about Eden, please visit: www.edenresearch.com.

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCUARURKUANAUR

Quick facts: Eden Research plc

Price: 7.5

Market: AIM
Market Cap: £15.54 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: Boost for Arkle Resources as Glencore takes stake in partner

Headlines from the Proactive UK newsroom. Irish mining junior Arkle Resources (LON:ARK) has received a boost after mining titan Glencore invested C$1mln into its partner on the Stonepark Zinc Project. Arkle holds a 23.44% stake in Stonepark, which lies to the south of an existing Glencore...

on 16/10/19